Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors - PubMed

Affiliations

• PMID: 17868033
• DOI: 10.1042/BJ20070779

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Nagma Khan et al. Biochem J. 2008.

Abstract

The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene expression through regulation of transcription. While HDACs can be subdivided into three main classes, the class I, class II and class III HDACs (sirtuins), it is presently unclear whether inhibiting multiple HDACs using pan-HDAC inhibitors, or targeting specific isoforms that show aberrant levels in tumours, will prove more effective as an anticancer strategy in the clinic. To address the above issues, we have tested a number of clinically relevant HDACis (HDAC inhibitors) against a panel of rhHDAC (recombinant human HDAC) isoforms. Eight rhHDACs were expressed using a baculoviral system, and a Fluor de Lystrade mark (Biomol International) HDAC assay was optimized for each purified isoform. The potency and selectivity of ten HDACs on class I isoforms (rhHDAC1, rhHDAC2, rhHDAC3 and rhHDAC8) and class II HDAC isoforms (rhHDAC4, rhHDAC6, rhHDAC7 and rhHDAC9) was determined. MS-275 was HDAC1-selective, MGCD0103 was HDAC1- and HDAC2-selective, apicidin was HDAC2- and HDAC3-selective and valproic acid was a specific inhibitor of class I HDACs. The hydroxamic acid-derived compounds (trichostatin A, NVP-LAQ824, panobinostat, ITF2357, vorinostat and belinostat) were potent pan-HDAC inhibitors. The growth-inhibitory effect of the HDACis on HeLa cells showed that both pan-HDAC and class-I-specific inhibitors inhibited cell growth. The results also showed that both pan-HDAC and class-I-specific inhibitor treatment resulted in increased acetylation of histones, but only pan-HDAC inhibitor treatment resulted in increased tubulin acetylation, which is in agreement with their activity towards the HDAC6 isoform.

Similar articles

• Identification of novel isoform-selective inhibitors within class I histone deacetylases.

  Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M. Hu E, et al. J Pharmacol Exp Ther. 2003 Nov;307(2):720-8. doi: 10.1124/jpet.103.055541. Epub 2003 Sep 15. J Pharmacol Exp Ther. 2003. PMID: 12975486

• Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.

  Weichert W, Röske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C. Weichert W, et al. Clin Cancer Res. 2008 Mar 15;14(6):1669-77. doi: 10.1158/1078-0432.CCR-07-0990. Clin Cancer Res. 2008. PMID: 18347167

• Expression and functional characterization of recombinant human HDAC1 and HDAC3.

  Li J, Staver MJ, Curtin ML, Holms JH, Frey RR, Edalji R, Smith R, Michaelides MR, Davidsen SK, Glaser KB. Li J, et al. Life Sci. 2004 Apr 16;74(22):2693-705. doi: 10.1016/j.lfs.2003.09.070. Life Sci. 2004. PMID: 15043985

• Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.

  Codd R, Braich N, Liu J, Soe CZ, Pakchung AA. Codd R, et al. Int J Biochem Cell Biol. 2009 Apr;41(4):736-9. doi: 10.1016/j.biocel.2008.05.026. Epub 2008 Aug 3. Int J Biochem Cell Biol. 2009. PMID: 18725319 Review.

• Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.

  Göttlicher M. Göttlicher M. Ann Hematol. 2004;83 Suppl 1:S91-2. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124690 Review.

Cited by

• Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.

  Singh BN, Zhou H, Li J, Tipton T, Wang B, Shao G, Gilbert EN, Li Q, Jiang SW. Singh BN, et al. Future Oncol. 2011 Dec;7(12):1415-28. doi: 10.2217/fon.11.124. Future Oncol. 2011. PMID: 22112317 Free PMC article. Review.

• Editorial: Natural Product Epigenetic Modulators and Inhibitors.

  Ntie-Kang F, Karaman Mayack B, Valente S, Battistelli C. Ntie-Kang F, et al. Front Pharmacol. 2021 Mar 4;12:651395. doi: 10.3389/fphar.2021.651395. eCollection 2021. Front Pharmacol. 2021. PMID: 33746763 Free PMC article. No abstract available.

• Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes.

  Alshawli AS, Wurdak H, Wood IC, Ladbury JE. Alshawli AS, et al. Mol Genet Genomic Med. 2020 Oct;8(10):e1429. doi: 10.1002/mgg3.1429. Epub 2020 Jul 27. Mol Genet Genomic Med. 2020. PMID: 32720471 Free PMC article.

• CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.

  Yang PM, Lin PJ, Chen CC. Yang PM, et al. Epigenetics. 2012 Apr;7(4):390-9. doi: 10.4161/epi.19373. Epub 2012 Apr 1. Epigenetics. 2012. PMID: 22419072 Free PMC article.

• Targeting Huntington's disease through histone deacetylases.

  Gray SG. Gray SG. Clin Epigenetics. 2011 Aug;2(2):257-77. doi: 10.1007/s13148-011-0025-7. Epub 2011 Feb 18. Clin Epigenetics. 2011. PMID: 22704341 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Guide to Pharmacology

• Miscellaneous

  • NCI CPTAC Assay Portal